DNA-PK inhibitor, M3814, as a radiation sensitizer in the treatment of neuroendocrine tumors

被引：0
|
作者：
Rychahou, Piotr [1 ]
Chauhan, Aman [2 ,3 ]
Chow, Zeta [1 ]
Izumi, Tadahidi [4 ]
Chen, Quan [5 ]
Lee, Eun Y. [6 ]
Napier, Dana [6 ]
Anthony, Lowell B. [2 ,3 ]
Cavnar, Michael J. [1 ]
Kunos, Charles [7 ]
Evers, B. Mark [1 ,3 ]
机构：
[1] Univ Kentucky, Dept Surg, Lexington, KY USA
[2] Univ Kentucky, Dept Internal Med Med Oncol, Lexington, KY USA
[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA
[4] Univ Kentucky, Markey Canc Ctr, Dept Toxicol & Canc Biol, Lexington, KY USA
[5] Univ Kentucky, Dept Radiat Med, Lexington, KY USA
[6] Univ Kentucky, Dept Pathol & Lab Med, Lexington, KY USA
[7] NIH, Washington, DC USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-6402
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6402
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Utilising DNA-PK inhibitor, M3814, as a radiation sensitizer
    Fatima, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2022, 34 : 40 - 40
  • [2] Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
    Zenke, Frank T.
    Zimmermann, Astrid
    Sirrenberg, Christian
    Dahmen, Heike
    Kirkin, Vladimir
    Pehl, Ulrich
    Grombacher, Thomas
    Wilm, Claudia
    Fuchss, Thomas
    Amendt, Christiane
    Vassilev, Lyubomir T.
    Blaukat, Andree
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (05) : 1091 - 1101
  • [3] DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
    Carr, Michael, I
    Zimmermann, Astrid
    Chiu, Li-Ya
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [4] DNA-PK inhibitor, M3814, as a new combination partner of Mylotarg in the treatment of acute myeloid leukemia
    Zimmermann, Astrid
    Carr, Michael
    Zenke, Frank T.
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] M3814: A novel investigational DNA-PK inhibitor to target DNA double strand break repair
    Zenke, F. T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] M3814, a novel investigational DNA-PK inhibitor: enhancing the effect of fractionated radiotherapy leading to complete regression of tumors in mice
    Zenke, Frank T.
    Zimmermann, Astrid
    Sirrenberg, Christian
    Dahmen, Heike
    Vassilev, Lubo
    Pehl, Ulrich
    Fuchss, Thomas
    Blaukat, Andree
    CANCER RESEARCH, 2016, 76
  • [7] TP53 status determines the fate of cancer cells exposed to ionizing radiation and DNA-PK inhibitor, M3814
    Sun, Qing
    Guo, Yige
    Liu, Xiaohong
    Czauderna, Frank
    Zenke, Frank
    Blaukat, Andree
    Vassilev, Lyubomir T.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] A multicenter phase I trial of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814 in patients with solid tumors.
    van Bussel, Mark
    Mau-Soerensen, Morten
    Damstrup, Lars
    Nielsen, Dorte
    Verheul, Henk M. W.
    Aftimos, Philippe Georges
    De Jonge, Maja J.
    Berghoff, Karin
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Antitumor Efficacy of M3814 as a Radiation Sensitizer in Neuroendocrine Tumor (NET) Preclinical Models
    Chauhan, Aman
    Rychahou, Piotr
    Izumi, Tadahide
    Wu, John
    Anthony, Lowell
    Evers, Mark
    Kunos, Charles
    PANCREAS, 2020, 49 (03) : 465 - 465
  • [10] Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
    Hannah C. Wise
    Gopakumar V. Iyer
    Kathleen Moore
    Sarah M. Temkin
    Sarah Gordon
    Carol Aghajanian
    Rachel N. Grisham
    Scientific Reports, 9
12345